Aurinia Pharmaceuticals Inc. — Director's Dealing 2021

Jun 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aurinia Pharmaceuticals Inc. (AUPH)
CIK: 0001600620
Period of Report: 2021-06-22

Reporting Person: Martin Michael Robert (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-22	Common Stock	S	5000	$13.76	Disposed	216861	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2021.

F2: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the sold date.